Crizotinib (formerly PF- 02341066), is an oral ATP-competitive SMI of c-MET, ALK and ROS1 [27], with a recommended dose of 250 mg B.D for patients with ROS1 + or ALK + metastatic NSCLC [28]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.